SCHEMBL266019

SCHEMBL266019

Cc1ccc(C=NNC(=O)c2cc(Br)ccc2NC(=O)c2ccc(CSc3ccncc3)cc2)cc1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.49
GAA P10253 1/20 0.49
ALDH1A1 P00352 5/20 0.48
POLB P06746 4/20 0.44
LMNA P02545 3/20 0.44
PKM P14618 3/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 2/20 0.44
HTT P42858 2/20 0.42
HPGD P15428 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
BLM P54132 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
KMT2A Q03164 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL273430 1.00 MAPT (0.49) MAPTGAAALDH1A1POLBLMNA
SCHEMBL267602 0.92 MAPT (0.53) MAPTGAAALDH1A1POLBLMNA
SCHEMBL273398 0.92 MAPT (0.53) MAPTGAAALDH1A1POLBLMNA
SCHEMBL273386 0.91 POLB (0.48) MAPTGAAALDH1A1POLBLMNA
SCHEMBL266993 0.91 POLB (0.48) MAPTGAAALDH1A1POLBLMNA
SCHEMBL274090 0.90 RAB9A (0.54) MAPTGAAALDH1A1POLBLMNA
SCHEMBL267884 0.90 RAB9A (0.54) MAPTGAAALDH1A1POLBLMNA
SCHEMBL269020 0.89 NPC1 (0.51) MAPTGAAALDH1A1POLBLMNA
SCHEMBL273396 0.89 NPC1 (0.51) MAPTGAAALDH1A1POLBLMNA
SCHEMBL266961 0.88 NPC1 (0.53) MAPTGAAALDH1A1POLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 MAPT 4195/4885GAA 1336/4885ALDH1A1 3022/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 MAPT 4648/4885GAA 1640/4885ALDH1A1 2872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.